Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This will be a pilot single-arm study consisting of 15 participants evaluating the use of
oritavancin in the final consolidation phase (last two weeks of treatment) of systemic
infections with Staphylococcus aureus (S. aureus) in opioid users.
The purpose of this pilot proposal is to collect information for a subsequent large,
randomized intervention. Primary endpoints will be 1) Safety and tolerability, and 2)
Duration of hospitalization and rate of recurrence.